The Oncology Institute Inc (TOI) is not a strong buy at this moment for a beginner investor with a long-term focus. Despite some positive revenue growth in the latest financials, the company's profitability metrics remain weak, and hedge funds are significantly selling the stock. Additionally, the stock lacks strong trading signals, and the upcoming earnings announcement introduces uncertainty. A hold position is recommended until more clarity is available post-earnings.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, RSI is in the neutral zone at 76.337, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its resistance level (R1: 2.952) in pre-market, which may limit further immediate upside.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market. However, implied volatility is high (130.42), suggesting elevated risk.

Technical Summary

Sell

Buy

Positive Catalysts

Revenue increased by 36.70% YoY in Q3 2025, indicating strong top-line growth. The company has an upcoming earnings announcement and investor call, which could provide further insights into its performance.

Neutral/Negative Catalysts

Net income remains negative at -$13.77M, and EPS dropped by -22.22% YoY. Hedge funds are aggressively selling the stock, with a 47487.34% increase in selling activity last quarter. Gross margin also declined slightly, reflecting operational challenges.

Financial Performance

In Q3 2025, revenue grew by 36.70% YoY to $136.56M. However, the company remains unprofitable, with a net loss of -$13.77M (a slight 4.14% improvement YoY). EPS dropped to -0.14 (-22.22% YoY), and gross margin declined to 12.59% (-1.72% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available for TOI.

3 Analyst Rating

Wall Street analysts forecast TOI stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.890

Low

Averages

6.67

High

Current: 2.890

Low

Averages

6.67

High

Needham

Buy

initiated

AI Analysis

2025-11-25

Reason

Needham

Price Target

AI Analysis

2025-11-25

initiated

Buy

Reason

Needham initiated coverage of Oncology Institute with a Buy rating and $5 price target. As value-based care adoption accelerates, Oncology Institute appears well positioned to help curb rising oncology costs, with early relationships typically starting in fee-for-service and expanding into downside risk, the analyst tells investors in a research note. Demand supports a durable 20%+ growth outlook, a shift toward VBC could lift EBITDA margins into the mid-single digits, and shares look undervalued ahead of expected positive EBITDA in Q4 and FY26, the firm says.

Needham

Matthew Shea

initiated

2025-11-25

Reason

Needham

Matthew Shea

Price Target

2025-11-25

initiated

Reason

Needham analyst Matthew Shea initiated coverage of Oncology Institute with a Buy rating and $5 price target. The need for solutions that can mitigate oncology cost trends "could not be more apparent," says the analyst, who views Oncology Institute as "a critical player in addressing this gap." The firm sees demand seeding durable 20%-plus topline growth and sees an opportunity for EBITDA margins to scale towards mid-single digits over the medium term as mix shifts towards value-based care, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TOI

Unlock Now

TOI Should I Buy

TOI Should I Buy

Should You Buy Oncology Institute Inc (TOI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch